{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:56:18Z","timestamp":1790848578764,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04385-0","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:26:18Z","timestamp":1783484778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and early outcomes in advanced intrahepatic cholangiocarcinoma: a descriptive case series"],"prefix":"10.1007","volume":"75","author":[{"given":"Runze","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"1","key":"4385_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4385_CR2","first-page":"198","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D et al (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73(2):198\u2013222","journal-title":"CA Cancer J Clin"},{"key":"4385_CR3","unstructured":"Benson, A.B., 3rd, et al., Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw, 2014. 12(8): p. 1152\u201382"},{"issue":"6","key":"4385_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT et al (2019) Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a Phase 2 clinical trial. JAMA Oncol 5(6):824\u2013830","journal-title":"JAMA Oncol"},{"key":"4385_CR5","unstructured":"Oh, D.Y., et al., Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid, 2022. 1(8): p. EVIDoa2200015"},{"issue":"19","key":"4385_CR6","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1097\/CM9.0000000000003258","volume":"137","author":"X Wang","year":"2024","unstructured":"Wang X et al (2024) Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers. Chin Med J (Engl) 137(19):2272\u20132293","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"4385_CR7","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.31092","volume":"72","author":"S Job","year":"2020","unstructured":"Job S et al (2020) Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 72(3):965\u2013981","journal-title":"Hepatology"},{"issue":"5","key":"4385_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D et al (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15(5):325\u2013340","journal-title":"Nat Rev Clin Oncol"},{"key":"4385_CR9","doi-asserted-by":"crossref","unstructured":"Villanueva, L., et al., Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. Journal of Clinical Oncology, 2023. 39(3_suppl): p. 321\u2013321. (conference abstract)","DOI":"10.1200\/JCO.2021.39.3_suppl.321"},{"issue":"12","key":"4385_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019276","volume":"99","author":"J Luo","year":"2020","unstructured":"Luo J et al (2020) Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: a preliminary result from CTILC study. Medicine (Baltimore) 99(12):e19276","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"4385_CR11","first-page":"6584","volume":"12","author":"Y Hu","year":"2020","unstructured":"Hu Y et al (2020) Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma. Am J Transl Res 12(10):6584\u20136598","journal-title":"Am J Transl Res"},{"issue":"1","key":"4385_CR12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","volume":"20","author":"M Ueno","year":"2020","unstructured":"Ueno M et al (2020) Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer 20(1):1105","journal-title":"BMC Cancer"},{"issue":"12","key":"4385_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00262-024-03841-z","volume":"73","author":"S Wang","year":"2024","unstructured":"Wang S et al (2024) Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study. Cancer Immunol Immunother 73(12):249","journal-title":"Cancer Immunol Immunother"},{"key":"4385_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751391","volume":"11","author":"Q Zhang","year":"2021","unstructured":"Zhang Q et al (2021) Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phase II study. Front Oncol 11:751391","journal-title":"Front Oncol"},{"key":"4385_CR15","doi-asserted-by":"crossref","unstructured":"Jian, Z., et al., Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial. Journal of Clinical Oncology. 39(15_suppl): p. 4099\u20134099. (conference abstract)","DOI":"10.1200\/JCO.2021.39.15_suppl.4099"},{"key":"4385_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.691380","volume":"11","author":"Y Ding","year":"2021","unstructured":"Ding Y et al (2021) Systemic sequential therapy of cisgem, tislelizumab, and lenvatinib for advanced intrahepatic cholangiocarcinoma conversion therapy. Front Oncol 11:691380","journal-title":"Front Oncol"},{"key":"4385_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.005","volume":"32","author":"M Ducreux","year":"2021","unstructured":"Ducreux M et al (2021) O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma. Ann Oncol 32:S217","journal-title":"Ann Oncol"},{"issue":"1","key":"4385_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM et al (2023) Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther 8(1):106","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4385_CR19","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z et al (2021) Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol 22(7):977\u2013990","journal-title":"Lancet Oncol"},{"key":"4385_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1494520","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang Z et al (2024) Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study. Front Immunol 15:1494520","journal-title":"Front Immunol"},{"key":"4385_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1101038","volume":"13","author":"YQ Zhang","year":"2023","unstructured":"Zhang YQ et al (2023) Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study. Front Oncol 13:1101038","journal-title":"Front Oncol"},{"key":"4385_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1397827","volume":"15","author":"R Zhao","year":"2024","unstructured":"Zhao R et al (2024) Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. Front Immunol 15:1397827","journal-title":"Front Immunol"},{"issue":"4","key":"4385_CR23","first-page":"437","volume":"24","author":"JB Kuhlmann","year":"2012","unstructured":"Kuhlmann JB et al (2012) Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 24(4):437\u2013443","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"4385_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000502510","volume":"64","author":"Y Wei","year":"2019","unstructured":"Wei Y et al (2019) Effectiveness and safety of combination therapy of transarterial chemoembolization and Apatinib for unresectable hepatocellular carcinoma in the Chinese population: a meta-analysis. Chemotherapy 64(2):94\u2013104","journal-title":"Chemotherapy"},{"issue":"1","key":"4385_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00280-019-04004-z","volume":"85","author":"J Liu","year":"2020","unstructured":"Liu J et al (2020) Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma. Cancer Chemother Pharmacol 85(1):69\u201376","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4385_CR26","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10637-022-01257-z","volume":"40","author":"P Yuan","year":"2022","unstructured":"Yuan P et al (2022) Combination of TACE and lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma. Invest New Drugs 40(5):1125\u20131132","journal-title":"Invest New Drugs"},{"issue":"1150","key":"4385_CR27","doi-asserted-by":"publisher","first-page":"20230079","DOI":"10.1259\/bjr.20230079","volume":"96","author":"Z Ning","year":"2023","unstructured":"Ning Z et al (2023) Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. Br J Radiol 96(1150):20230079","journal-title":"Br J Radiol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04385-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04385-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04385-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:06:27Z","timestamp":1790845587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04385-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4385"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04385-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a single-center retrospective study. All procedures were in line with the ethical principles of the Declaration of Helsinki and relevant national medical research regulations. The study protocol has been reviewed and approved by the Ethics Committee of the Cancer Hospital of Chinese Academy of Medical Sciences, with the approval number [NCC1996]. Given the retrospective nature, the requirement for individual informed consent was waived by the aforementioned Ethics Committee, and all data used were retrieved from the hospital\u2019s HIS electronic medical record system with legitimate authorization, ensuring compliance with ethical standards for medical research involving human subjects.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"242"}}